Antitrust Antitrust

Comment: Cigna, Humana have limited opportunities to reduce regulatory risk

By Ilana Kowarski, Ben Brody and Flavia Fortes
  • 08 Dec 2023 17:51
  • 08 Dec 2023 19:12
Health insurers Cigna and Humana, which are reportedly contemplating a $140 billion merger, would have a hard time convincing antitrust regulators that any potential concerns with their deal could be resolved with remedies and that, because their businesses are complementary, the transaction would actually benefit consumers.
Concerns around overlaps in

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Flavia Fortes

Global Head of Mergers


Flavia writes about merger control, antitrust enforcement and litigation in the U.S. and Brazil. Before joining MLex, Flavia worked as an Antitrust Consultant in the Federal Trade Commission's Office of International Affairs and as a Research Fellow for the American Antitrust Institute. She has written on the intersection of antitrust law and intellectual property law in technology-driven and innovative markets.

Discover MLex

Stay on top of global regulatory developments

Latest News